💉 Feline/Canine Chronic Kidney Disease Staging (IRIS) Simulator

Stage 1 — Early Kidney Disease Before Azotemia Appears

Placeholder: early kidney damage exists before blood creatinine rises.

• <1.6: Creatinine (mg/dL, placeholder range)
• <18: SDMA (μg/dL, placeholder range)
• ~0-25%: Nephrons lost (placeholder estimate)
• None/mild: Clinical signs (placeholder summary)

Detecting disease before azotemia

Placeholder: imaging, urinalysis, and SDMA can flag risk early.

Stage 2 — Mild Azotemia With Reduced Renal Reserve

Placeholder: creatinine climbs mildly as functioning nephrons decline.

• 1.6-2.8: Creatinine (mg/dL, placeholder range)
• 18-25: SDMA (μg/dL, placeholder range)
• ~25-50%: Nephrons lost (placeholder estimate)
• Subtle: Clinical signs (placeholder summary)

Managing early mild azotemia

Placeholder: diet change and monitoring begin at this stage.

Stage 3 — Moderate Azotemia and Emerging Clinical Signs

Placeholder: moderate nephron loss brings noticeable clinical signs.

• 2.9-5.0: Creatinine (mg/dL, placeholder range)
• 26-38: SDMA (μg/dL, placeholder range)
• ~50-75%: Nephrons lost (placeholder estimate)
• Moderate: Clinical signs (placeholder summary)

Interventions at moderate stage

Placeholder: phosphate binders and renal diet become important.

Stage 4 — Severe Azotemia and Uremic Risk

Placeholder: severe nephron loss risks uremic crisis without care.

• >5.0: Creatinine (mg/dL, placeholder range)
• >38: SDMA (μg/dL, placeholder range)
• ~75-95%: Nephrons lost (placeholder estimate)
• Severe: Clinical signs (placeholder summary)

Intensive management at severe stage

Placeholder: hospitalization and dialysis may be considered.

Substaging by Proteinuria and Blood Pressure

Placeholder: proteinuria and hypertension refine prognosis within stage.

• <0.2 / 0.2-0.4 / >0.4: UPC ratio (placeholder cutoffs)
• <150 / 150-179 / ≥180: Systolic BP (placeholder cutoffs)
• Low/Med/High: Risk tiers (placeholder summary)
• Frequent: Rechecks (placeholder guidance)

Why substaging matters

Placeholder: proteinuria and blood pressure predict progression risk.

Placeholder: substage guides added therapy beyond IRIS stage alone.